newsfilter
← Latest News
PR Newswire·

Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

  • Halozyme Therapeutics will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET.
  • CEO Dr. Helen Torley & CFO Nicole LaBrosse will present preliminary unaudited full-year 2025 revenue results, updated 2026-2028 financial guidance, & a business update.
  • The live call is available via pre-registration link, webcast through the Investors section of Halozyme.com, & a recording will be posted post-call.
  • Halozyme's ENHANZE drug delivery technology, utilizing rHuPH20, has served over one million patients across ten commercialized products in 100+ global markets.
  • Key licensing partners for ENHANZE include Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai, Acumen, & Merus.
  • Halozyme is developing Hypercon, a microparticle technology for high-concentration biologics to reduce injection volume, licensed to Johnson & Johnson, Eli Lilly, & argenx.
  • The company commercializes drug-device combination products, including proprietary offerings Hylenex & XYOSTED, & collaborates with Teva Pharmaceuticals & McDermott Laboratories.
  • Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ, Minnetonka, MN, & Boston, MA.
  • Investor Relations contact Tram Bui can be reached at 609-359-3016.